AVBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
ArriVent BioPharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$17.94+1.28 (+7.68%)
Close on Oct 19, 2026
- Market cap
- $854.07M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.57 (−8.05%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $854.07M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.33
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$163.74M
- EPS, diluted
- -$3.67
- Book value per share
- $7.71
- Diluted shares
- 48M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
-$175.94M
Net income
-$163.74M
EPS, diluted
-$3.67
Reported periodTrailing twelve months